SCHEMBL1972883

SCHEMBL1972883

CCOC(=O)c1ncc2cc(C=Cc3ccccc3)sc2c1O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.42
HPGD P15428 4/20 0.42
RAB9A P51151 4/20 0.42
LMNA P02545 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
ADORA3 P0DMS8 3/20 0.42
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
KDM4E B2RXH2 3/20 0.41
MAPT P10636 3/20 0.41
XBP1 P17861 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
POLB P06746 1/20 0.40
NPC1 O15118 3/20 0.39
CDC7 O00311 1/20 0.39
TRPM8 Q7Z2W7 1/20 0.39
DBF4 Q9UBU7 1/20 0.39
PPARG P37231 1/20 0.39
TGFBR1 P36897 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1972881 1.00 ALDH1A1 (0.42) ALDH1A1HPGDRAB9ALMNANPSR1
SCHEMBL1974215 0.79 CYP1A2 (0.45) ALDH1A1HPGDRAB9ALMNAMEN1
SCHEMBL968479 0.79 EGLN1 (0.54)
SCHEMBL1972406 0.77 RAB9A (0.47) ALDH1A1HPGDRAB9ALMNANPSR1
SCHEMBL1973778 0.76 ALDH1A1 (0.40) ALDH1A1HPGDNPSR1MEN1KMT2A
SCHEMBL1976490 0.73 HPGD (0.41) ALDH1A1HPGDNPSR1KMT2AKDM4E
SCHEMBL1974914 0.72 ALDH1A1 (0.40) ALDH1A1HPGDNPSR1MEN1KMT2A
SCHEMBL2880781 0.71 CDC7 (0.56) ALDH1A1RAB9ALMNAMEN1KMT2A
SCHEMBL2886841 0.70 P2RX3 (0.43) ALDH1A1HPGDRAB9ALMNANPSR1
SCHEMBL1972309 0.70 MAPT (0.57) ALDH1A1HPGDMEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9000006-B2 Thienopyridine compounds, and methods of use thereof FIBROGEN, INC. (US) 2015-04-07 US disclosed
US-20140221422-A1 NOVEL THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF FIBROGEN, INC. (US) 2014-08-07 US disclosed
US-8703795-B2 Thienopyridine compounds, and methods of use thereof FIBROGEN, INC. (US) 2014-04-22 US disclosed
EP-1866318-B1 THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF FIBROGEN INC (US) 2011-06-22 EP disclosed
EP-1866318-A2 THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF FIBROGEN, INC. (US) 2007-12-19 EP disclosed
WO-2006094292-A2 THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF FIBROGEN, INC. (US) 2006-09-08 WO disclosed
US-20060199836-A1 Novel thienopyridine compounds, and methods of use thereof FIBROGEN, INC. 2006-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221422-A1 NOVEL THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF HIF1AN, HIF1A, EGLN2 ALDH1A1 488/4885HPGD 21/4885RAB9A 4193/4885
US-20060199836-A1 Novel thienopyridine compounds, and methods of use thereof HIF1AN, HIF1A, EGLN2 ALDH1A1 488/4885HPGD 21/4885RAB9A 4193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.